Vanda Pharmaceuticals (VNDA) Income from Continuing Operations (2010 - 2026)

Vanda Pharmaceuticals has disclosed Income from Continuing Operations across 17 years of filings, most recently posting 48524000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 48524000.0, down 64.52% year-over-year; the trailing twelve-month figure through Mar 2026 was 239530000.0 (down 441.53% YoY), and the FY2025 annual result was 220474000.0, down 1066.53% from the prior year.
• Income from Continuing Operations came in at 48524000.0 for Q1 2026 at Vanda Pharmaceuticals, up from 141229000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 6861000.0 in Q4 2022 to a low of 141229000.0 in Q4 2025.
• The 5-year median for Income from Continuing Operations is 4518000.0 (2024), against an average of 16422235.29.
• Across the five-year window, Income from Continuing Operations soared 150.2% in 2023 and plunged 4000.73% in 2024, its largest moves.
• Vanda Pharmaceuticals' Income from Continuing Operations stood at 6861000.0 in 2022, then plunged by 134.85% to 2391000.0 in 2023, then sank by 103.93% to 4876000.0 in 2024, then plunged by 2796.41% to 141229000.0 in 2025, then jumped by 65.64% to 48524000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 48524000.0 (Q1 2026), 141229000.0 (Q4 2025), and 22590000.0 (Q3 2025), per Business Quant data.